Primary Pulmonary Hypertension
What is primary pulmonary hypertension (PPH)?
Pulmonary hypertension is a lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels.
Primary pulmonary hypertension has been associated with the appetite suppressants fenfluramine and dexfenfluramine (fen/phen), which were taken off the market in 1997. In the U.S., there are an estimated 500 to 1,000 new cases diagnosed each year, but the actual number of cases is unknown. It is most common in women between the ages of 21 and 40; however, anyone can develop it.
What are the causes of PPH?
The exact cause of PPH is unknown. Research has linked primary pulmonary hypertension to genetic or familial predisposition. Researchers believe the blood vessels are particularly sensitive to certain internal or external factors, and constrict, or narrow, when exposed to these factors, such as an immune system factor, or sensitivity to drugs or other chemicals.
Secondary pulmonary hypertension occurs as a result of the effects of other conditions which may include diseases of the heart or lungs, a blood clot in the lungs, or a condition called scleroderma.
What are the symptoms of PPH?
The following are the most common symptoms for pulmonary hypertension. However, each individual may experience symptoms differently. Symptoms may include:
Difficulty in breathing (dyspnea)
Fainting spells (syncope)
Swelling in the ankles or legs (edema)
Bluish lips and skin (cyanosis)
Chest pain (angina)
Trouble getting enough air
Palpitations, strong throbbing sensations brought on by increased heart rate
More severe symptoms indicate a more advanced disease. In advanced stages, the patient:
Is able to perform minimal activities
Has symptoms even when resting
May become bedridden if the disease becomes worse
The symptoms of primary pulmonary hypertension may resemble other conditions or medical problems. Consult your doctor for a diagnosis.
How is PPH diagnosed?
Pulmonary hypertension is rarely discovered in a routine medical examination, and in its later stages, the signs of the disease can be confused with other conditions affecting the heart and lungs.
Pulmonary hypertension is a diagnosis of exclusion. Diagnostic procedures may include:
Electrocardiogram (EKG or ECG). A test that records the electrical activity of the heart, shows abnormal rhythms (arrhythmias or dysrhythmias), and detects heart muscle damage.
Echocardiogram (echo). A procedure that evaluates the structure and function of the heart by using sound waves recorded on an electronic sensor that produce a moving picture of the heart and heart valves.
Pulmonary function tests. Diagnostic tests that help to measure the lungs' ability to move air into and out of the lungs effectively. The tests are usually performed with special machines into which the person must breathe.
Perfusion lung scan. A nuclear medicine procedure that can detect a blood clot in the artery leading to the lung. This procedure can also assess the function of the lungs.
Cardiac catheterization. A procedure that evaluates blood flow to the heart muscle, blockage of coronary arteries, congenital heart defects, functioning of the heart valves, and other heart structures. A small catheter is advanced from a blood vessel in the groin or arm through the aorta to the heart.
Treatment for PPH
Specific treatment will be determined by your doctor based on:
Your age, overall health, and medical history
Extent of the disease
Your tolerance for specific medications, procedures, or therapies
Expectations for the course of the disease
Your opinion or preference
Treatment may include one or more of the following: